Mitochondria Profoundly Influence Apolipoprotein E Biology.

BACKGROUND Mitochondria can trigger Alzheimer's disease (AD)-associated molecular phenomena, but how mitochondria impact apolipoprotein E (APOE; apoE) is not well known. OBJECTIVE Consider whether and how mitochondrial biology influences APOE and apoE biology. METHODS We measured APOE expression in human SH-SY5Y neuronal cells with different forms of mitochondrial dysfunction including total, chronic mitochondrial DNA (mtDNA) depletion (ρ0 cells); acute, partial mtDNA depletion; and toxin-induced mitochondrial dysfunction. We further assessed intracellular and secreted apoE protein levels in the ρ0 cells and interrogated the impact of transcription factors and stress signaling pathways known to influence APOE expression. RESULTS SH-SY5Y ρ0 cells exhibited a 65-fold increase in APOE mRNA, an 8-fold increase in secreted apoE protein, and increased intracellular apoE protein. Other models of primary mitochondrial dysfunction including partial mtDNA-depletion, toxin-induced respiratory chain inhibition, and chemical-induced manipulations of the mitochondrial membrane potential similarly increased SH-SY5Y cell APOE mRNA. We explored potential mediators and found in the ρ0 cells knock-down of the C/EBPα and NFE2L2 (Nrf2) transcription factors reduced APOE mRNA. The activity of two mitogen-activated protein kinases, JNK and ERK, also strongly influenced ρ0 cell APOE mRNA levels. CONCLUSION Primary mitochondrial dysfunction either directly or indirectly activates APOE expression in a neuronal cell model by altering transcription factors and stress signaling pathways. These studies demonstrate mitochondrial biology can influence the biology of the APOE gene and apoE protein, which are implicated in AD.

[1]  Joshua T. Burdick,et al.  A common transcriptional mechanism involving R-loop and RNA abasic site regulates an enhancer RNA of APOE. , 2022, Nucleic acids research.

[2]  G. Rimbach,et al.  Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function , 2022, Cellular and Molecular Life Sciences.

[3]  A. Goate,et al.  The role of mitochondrial genome abundance in Alzheimer's disease , 2022, medRxiv.

[4]  Christopher D. Brown,et al.  Identifying differential regulatory control of APOE ɛ4 on African versus European haplotypes as potential therapeutic targets , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  P. D. De Jager,et al.  Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain , 2021, Molecular Neurodegeneration.

[6]  D. Bennett,et al.  Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer’s disease , 2021, Nature Neuroscience.

[7]  H. Anderson,et al.  Bioenergetic and inflammatory systemic phenotypes in Alzheimer’s disease APOE ε4‐carriers , 2021, Aging cell.

[8]  A. Picca,et al.  Cell Death and Inflammation: The Role of Mitochondria in Health and Disease , 2021, Cells.

[9]  S. Yu,et al.  C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease , 2020, Molecular Psychiatry.

[10]  S. Laufer,et al.  c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases , 2020, International journal of molecular sciences.

[11]  R. Swerdlow,et al.  Mitochondrial DNA Manipulations Affect Tau Oligomerization. , 2020, Journal of Alzheimer's disease : JAD.

[12]  D. Michaelson,et al.  Altered mitochondrial dynamics and function in APOE4-expressing astrocytes , 2020, Cell Death & Disease.

[13]  M. Sabbagh,et al.  Effect of ApoE isoforms on mitochondria in Alzheimer disease , 2020, Neurology.

[14]  C. Giorgi,et al.  The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders , 2020, Journal of clinical medicine.

[15]  G. Bu,et al.  Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies , 2019, Nature Reviews Neurology.

[16]  D. Blackburn,et al.  Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease , 2018, Journal of molecular biology.

[17]  Liqin Zhao,et al.  Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention , 2018, The Journal of Neuroscience.

[18]  L. Kritharides,et al.  Cell-specific production, secretion, and function of apolipoprotein E , 2018, Journal of Molecular Medicine.

[19]  R. Swerdlow Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[20]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[21]  R. Swerdlow,et al.  Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients , 2017, Redox biology.

[22]  B. Wieringa,et al.  The SH-SY5Y cell line in Parkinson’s disease research: a systematic review , 2017, Molecular Neurodegeneration.

[23]  G. Landreth,et al.  LXR Regulation of Brain Cholesterol: From Development to Disease , 2016, Trends in Endocrinology & Metabolism.

[24]  A. Friedman C/EBPα in normal and malignant myelopoiesis , 2015, International Journal of Hematology.

[25]  R. Mahley,et al.  Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology , 2012, Neuron.

[26]  R. Swerdlow Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. , 2012, Antioxidants & redox signaling.

[27]  L. Bekris,et al.  Functional Analysis of APOE Locus Genetic Variation Implicates Regional Enhancers in the Regulation of Both TOMM40 and APOE , 2011, Journal of Human Genetics.

[28]  Ying Xia,et al.  c-Jun, at the crossroad of the signaling network , 2011, Protein & Cell.

[29]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[30]  R. Mahley,et al.  Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease* , 2010, The Journal of Biological Chemistry.

[31]  G. Fiskum,et al.  Neuroprotection through stimulation of mitochondrial antioxidant protein expression. , 2010, Journal of Alzheimer's disease : JAD.

[32]  E. Choi,et al.  Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.

[33]  E. Reiman,et al.  Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. , 2010, Journal of Alzheimer's disease : JAD.

[34]  L. Opitz,et al.  A New Paradigm for MAPK: Structural Interactions of hERK1 with Mitochondria in HeLa Cells , 2009, PloS one.

[35]  C. Chu,et al.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. , 2009, Mitochondrion.

[36]  T. Mazzone,et al.  Peroxisome Proliferator-activated Receptor γ Stimulation of Adipocyte ApoE Gene Transcription Mediated by the Liver Receptor X Pathway* , 2009, Journal of Biological Chemistry.

[37]  T. Mazzone,et al.  Oxidative Stress Regulates Adipocyte Apolipoprotein E and Suppresses Its Expression in Obesity , 2008, Diabetes.

[38]  G. Schellenberg,et al.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. , 2008, Journal of Alzheimer's disease : JAD.

[39]  M. Simionescu,et al.  Inflammatory Signaling Pathways Regulating ApoE Gene Expression in Macrophages* , 2007, Journal of Biological Chemistry.

[40]  George Perry,et al.  Alzheimer disease, the two-hit hypothesis: an update. , 2007, Biochimica et biophysica acta.

[41]  V. Haroutunian,et al.  Correlation of the clinical severity of alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA) , 2001, Journal of Molecular Neuroscience.

[42]  D. Lahiri Apolipoprotein E as a target for developing new therapeutics for Alzheimer’s disease based on studies from protein, RNA, and regulatory region of the gene , 2007, Journal of Molecular Neuroscience.

[43]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Beal,et al.  Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Xiongwei Zhu,et al.  Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.

[47]  R. Mahley,et al.  Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.

[48]  T. Lanz,et al.  Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype , 2003, Neurobiology of Disease.

[49]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[50]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[51]  Xiongwei Zhu,et al.  Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.

[52]  D. Talmage,et al.  Apolipoprotein E Inhibits Serum-stimulated Cell Proliferation and Enhances Serum-independent Cell Proliferation* , 2001, The Journal of Biological Chemistry.

[53]  R. Swerdlow,et al.  Alzheimer's disease cybrids replicate β‐amyloid abnormalities through cell death pathways , 2000 .

[54]  J. Wands,et al.  Mitochondrial DNA Damage as a Mechanism of Cell Loss in Alzheimer's Disease , 2000, Laboratory Investigation.

[55]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[56]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[57]  R. Swerdlow,et al.  Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. , 1998, Biochemical and biophysical research communications.

[58]  R. Davis,et al.  Cybrids in Alzheimer's disease: A cellular model of the disease? , 1997, Neurology.

[59]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[60]  W. Parker,et al.  Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties , 1996, Journal of neurochemistry.

[61]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[62]  L. Mahadevan,et al.  Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun , 1994, Molecular and cellular biology.